About AFYX Therapeutics
AFYX Therapeutics is a company based in Copenhagen (Denmark) founded in 2013. AFYX Therapeutics has raised $33.34 million across 6 funding rounds from investors including European Union, Novoseeds and EIC Fund. The company has 1 employees as of January 31, 2024. AFYX Therapeutics offers products and services including Gefena, Diaphine, and Nimorazole. AFYX Therapeutics operates in a competitive market with competitors including Avidity Biosciences, Univercells, Sutro Biopharma, Vividion Therapeutics and Straumann Group, among others.
- Headquarter Copenhagen, Denmark
- Employees 1 as on 31 Jan, 2024
- Stage Minicorn
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Afyx Therapeutics A/S
-
Annual Revenue
Not available
-
Net Profit
-$1.22 M (USD)69as on Dec 31, 2022
-
EBITDA
Not available
-
Total Equity Funding
$33.34 M (USD)
in 6 rounds
-
Latest Funding Round
$551.04 K (USD), Grant
Aug 31, 2019
-
Investors
European Union
& 7 more
-
Employee Count
1
as on Jan 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of AFYX Therapeutics
AFYX Therapeutics offers a comprehensive portfolio of products and services, including Gefena, Diaphine, and Nimorazole.
Tablet used for induction of labor in medical settings.
Product contributing to revenue through sales growth.
Product sold primarily in Norway for medical applications.
Funding Insights of AFYX Therapeutics
AFYX Therapeutics has successfully raised a total of $33.34M across 6 strategic funding rounds. The most recent funding activity was a Grant round of $551.04 thousand completed in August 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in AFYX Therapeutics
AFYX Therapeutics has secured backing from 8 investors, including venture fund and institutional investors. Prominent investors backing the company include European Union, Novoseeds and EIC Fund.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Government agency and accelerator focusing on innovative startups and SMEs
|
Locked | Locked | Locked | |
|
Biotech funding, drug development support, and investment in life sciences.
|
Locked | Locked | Locked | |
|
Life science companies are funded through venture capital investments.
|
Locked | Locked | Locked |
Investor details for AFYX Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by AFYX Therapeutics
Investment portfolio details for AFYX Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - AFYX Therapeutics
Detailed financials for AFYX Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Afyx Therapeutics Comparisons
Peer comparison for AFYX Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of AFYX Therapeutics
AFYX Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Avidity Biosciences, Univercells, Sutro Biopharma, Vividion Therapeutics and Straumann Group, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Antibody-siRNA complexes are developed for cancer treatment.
|
|
| Locked | Locked | Locked |
Biomanufacturing technologies are supplied for biopharma antibody and vaccine production.
|
|
| Locked | Locked | Locked |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis.
|
|
| Locked | Locked | Locked |
Developing novel drugs based on a proteome-wide ligand and target discovery platform
|
|
| Locked | Locked | Locked |
Dental implants and regenerative dentistry products are developed.
|
|
| Locked | Locked | Locked |
RNA-editing technologies are provided for precision medicine applications.
|
Detailed competitors of AFYX Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Afyx Therapeutics
Complete news archive for AFYX Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about AFYX Therapeutics
AFYX Therapeutics was founded in 2013 and raised its 1st funding round 2 years after it was founded.
AFYX Therapeutics is headquartered in Copenhagen, Denmark.
AFYX Therapeutics is a funded company, having raised a total of $33.34M across 6 funding rounds to date.
As of Jan 31, 2024, the latest employee count at AFYX Therapeutics is 1.
AFYX Therapeutics was founded in 2013 in Copenhagen, Denmark, within the biotechnology sector. Focus is placed on developing self-adhesive drug patches, such as Rivelin, for uniform delivery of therapies to mucosal linings. A pipeline of targeted treatments is advanced for oral health conditions, including Head and Neck Cancer and Oral Lichen Planus, addressing unmet needs in mucosal diseases. Operations center on innovative delivery systems for these applications.
AFYX Therapeutics's top competitors include Sutro Biopharma, Synthego and Avidity Biosciences.
AFYX Therapeutics offers Gefena, Diaphine, and Nimorazole.
AFYX Therapeutics has 8 investors. Key investors include European Union, Novoseeds, EIC Fund, Sofinnova, and Lundbeck Foundation.
The valuation of AFYX Therapeutics is $26.56M as of Apr 2017.